Trial · NCT06973304
Registered outcomes23
Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.
1 to 20 of 23
Download this page as JSON| List | Outcome | Time frame | Description |
|---|---|---|---|
| Primary | Percentage of Participants Who Achieved At Least 20 Percent (%) Reduction From Baseline in Weekly Parenteral Support (PS) Volume at Week 20 and Maintained Through Week 24 | Up to Week 24 | |
| Secondary | Absolute Change From Baseline in Weekly PS Volume up to Week 24 | Baseline up to Week 24 | |
| Secondary | Percent Change From Baseline in Weekly PS Volume up to Week 24 | Baseline up to Week 24 | |
| Secondary | Absolute Change From Baseline in Days Per Week of PS up to Week 24 | Baseline up to Week 24 | |
| Secondary | Percent Change From Baseline in Days Per Week of PS up to Week 24 | Baseline up to Week 24 | |
| Secondary | Number of Participants Who Achieved At Least 20% Reduction From Baseline in Weekly PS Volume at each visit | Up to Week 24 | |
| Secondary | Number of Participants With At Least a 20% Reduction From Baseline in Weekly PS at Week 20 and Maintained Through Week 24 | Baseline, Week 20 and Week 24 | |
| Secondary | Number of Participants With At Least a 2-liter Reduction From Baseline in Weekly PS at Week 20 and Maintained Through Week 24 | Baseline, Week 20 and Week 24 | |
| Secondary | Number of Participants who are able to Completely Wean off of PS support at Week 24 | At Week 24 | |
| Secondary | Time From First Dose to Time of Completely Weaning off of PS Support | Up to Week 24 | |
| Secondary | AUC0-inf: Area Under the Plasma Concentration-time Curve From Time 0 to Time of Infinity for Teduglutide | Predose, 1, 2, 4, 6, 8, and 10 hours post-dose | |
| Secondary | AUC0-last: Area Under the Plasma Concentration-time Curve From Time 0 to Time of the Last Quantifiable Concentration for Teduglutide | Predose, 1, 2, 4, 6, 8, and 10 hours post-dose | |
| Secondary | Cmax: Maximum Observed Plasma Concentration for Teduglutide | Predose, 1, 2, 4, 6, 8, and 10 hours post-dose | |
| Secondary | Tmax: Time to Reach the Cmax for Teduglutide | Predose, 1, 2, 4, 6, 8, and 10 hours post-dose | |
| Secondary | T1/2: Terminal Phase Half-life for Teduglutide | Predose, 1, 2, 4, 6, 8, and 10 hours post-dose | |
| Secondary | CL/F: Apparent Clearance for Teduglutide | Predose, 1, 2, 4, 6, 8, and 10 hours post-dose | |
| Secondary | V/F: Apparent Volume of Distribution During the Terminal Elimination Phase for Teduglutide | Predose, 1, 2, 4, 6, 8, and 10 hours post-dose | |
| Secondary | Plasma Concentrations of Teduglutide | At Week 4 and Week 24 | |
| Secondary | Number of Participants With Positive Antidrug Antibodies (Neutralizing and Non-neutralizing) | Baseline, Week 4, and Week 24 | |
| Secondary | Number of Participants Who Experienced At Least One Treatment-emergent Adverse Event (TEAE), Serious Adverse Event (SAE), and Adverse Event of Special Interest (AESI) | From first dose of study drug up to follow-up (Week 48) |
Source ClinicalTrials.govtrials-2026-11-12-0.5.0
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/trials/v1/NCT06973304/registered